The Double-edged Sword of Diabetes Drug Development

Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.

Some of the most notable recent fund raisings and collaboration activity for young companies are centered on diabetes drug development.

Understandably so, as the statistics on the incidence and impact of diabetes are both daunting and well known. Diabetes is...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip